Paolo G Artini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5824212/publications.pdf

Version: 2024-02-01

94 papers

2,798 citations

30 h-index 197736 49 g-index

96 all docs 96 docs citations

96 times ranked 2936 citing authors

#	Article	IF	CITATIONS
1	Cellular and molecular aspects of ovarian follicle ageing. Human Reproduction Update, 2008, 14, 131-142.	5.2	342
2	Female Infertility Related to Thyroid Autoimmunity: The Ovarian Follicle Hypothesis. American Journal of Reproductive Immunology, 2011, 66, 108-114.	1.2	136
3	Cryopreservation and oxidative stress in reproductive cells. Gynecological Endocrinology, 2010, 26, 563-567.	0.7	132
4	The role of color doppler imaging in the diagnosis of polycystic ovary syndrome. American Journal of Obstetrics and Gynecology, 1995, 172, 108-113.	0.7	130
5	Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecological Endocrinology, 2013, 29, 375-379.	0.7	100
6	Evidence for a role for the neurosteroid allopregnanolone in the modulation of reproductive function in female rats. European Journal of Endocrinology, 1995, 133, 375-380.	1.9	77
7	Changes in vascular endothelial growth factor levels and the risk of ovarian hyperstimulation syndrome in women enrolled in an in vitro fertilization program. Fertility and Sterility, 1998, 70, 560-564.	0.5	71
8	Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecological Endocrinology, 2012, 28, 969-973.	0.7	71
9	Ovarian response to combined growth hormone-gonadotropin treatment in patients resistant to induction of superovulation. Gynecological Endocrinology, 1989, 3, 125-133.	0.7	63
10	Vascular endothelial growth factor and basic fibroblast growth factor in polycystic ovary syndrome during controlled ovarian hyperstimulation. Gynecological Endocrinology, 2006, 22, 465-470.	0.7	60
11	Vascular endothelial growth factor and interleukin-8 in ovarian cystic pathology. Fertility and Sterility, 2001, 75, 1218-1221.	0.5	54
12	Colour Doppler changes and thromboxane production after ovarian stimulation with gonadotrophin-releasing hormone agonist. Human Reproduction, 1997, 12, 2477-2482.	0.4	53
13	Effects of reproductive aging and postovulatory aging on the maintenance of biological competence after oocyte vitrification: insights from the mouse model. Theriogenology, 2011, 76, 864-873.	0.9	52
14	Vascular endothelial growth factor and its soluble receptor in patients with polycystic ovary syndrome undergoing IVF. Human Fertility, 2009, 12, 40-44.	0.7	50
15	Follicular fluid VEGF levels directly correlate with perifollicular blood flow in normoresponder patients undergoing IVF. Journal of Assisted Reproduction and Genetics, 2008, 25, 183-186.	1.2	49
16	Peroxisome Proliferator-Activated Receptors in Female Reproduction and Fertility. PPAR Research, 2016, 2016, 1-12.	1.1	46
17	Ultrasonographic patterns of polycystic ovaries: color Doppler and hormonal correlations. Ultrasound in Obstetrics and Gynecology, 1998, 11, 332-336.	0.9	45
18	MicroRNAs Are Stored in Human MII Oocyte and Their Expression Profile Changes in Reproductive Aging. Biology of Reproduction, 2016, 95, 131-131.	1.2	44

#	Article	IF	CITATIONS
19	Infertility and pregnancy loss in euthyroid women with thyroid autoimmunity. Gynecological Endocrinology, 2013, 29, 36-41.	0.7	42
20	DHEA supplementation improves follicular microenviroment in poor responder patients. Gynecological Endocrinology, 2012, 28, 669-673.	0.7	41
21	Office Vaginoscopic Hysteroscopy in Infertile Women: Effects of Gynecologist Experience, Instrument Size, and Distention Medium on Patient Discomfort. Journal of Minimally Invasive Gynecology, 2010, 17, 344-350.	0.3	40
22	SIRT1 participates in the response to methylglyoxal-dependent glycative stress in mouse oocytes and ovary. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 1389-1401.	1.8	39
23	Membrane integrity evaluation in rabbit spermatozoa. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2002, 102, 53-56.	0.5	37
24	Fertility and endocrine outcome after robot-assisted laparoscopic myomectomy (RALM). Gynecological Endocrinology, 2013, 29, 79-82.	0.7	36
25	The Natural Carotenoid Crocetin and the Synthetic Tellurium Compound AS101 Protect the Ovary against Cyclophosphamide by Modulating SIRT1 and Mitochondrial Markers. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-14.	1.9	35
26	Uterine and ovarian blood flow measurement. Does the full bladder modify the flow resistance?. Acta Obstetricia Et Gynecologica Scandinavica, 1994, 73, 716-718.	1.3	33
27	Intrafollicular insulin-like growth factor-Il levels in normally ovulating women and in patients with polycystic ovary syndrome. Fertility and Sterility, 1996, 65, 739-745.	0.5	32
28	Vascular endothelial growth factor, interleukin-6 and interleukin-2 in serum and follicular fluid of patients with ovarian hyperstimulation syndrome. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2002, 101, 169-174.	0.5	32
29	Mitochondrial Sirtuins in Reproduction. Antioxidants, 2021, 10, 1047.	2.2	32
30	Human Breast Milk: Exploring the Linking Ring Among Emerging Components. Frontiers in Pediatrics, 2018, 6, 215.	0.9	31
31	Activin ?A subunit is expressed in bovine oviduct. Molecular Reproduction and Development, 1995, 40, 286-291.	1.0	30
32	Effect of dalteparin sodium administration on IVF outcome in non-thrombophilic young women: a pilot study. Reproductive BioMedicine Online, 2011, 22, 615-620.	1.1	30
33	Gene expression profiles of cumulus cells obtained from women treated with recombinant human luteinizing hormone + recombinant human follicle-stimulating hormone or highly purified human menopausal gonadotropin versus recombinant human follicle-stimulating hormone alone. Fertility and Sterility. 2013, 99, 2000-2008.e1.	0.5	28
34	Thyroid peroxidase identified in human granulosa cells: another piece to the thyroid-ovary puzzle?. Gynecological Endocrinology, 2017, 33, 574-576.	0.7	28
35	Ovarian response to controlled ovarian stimulation in women with different polycystic ovary syndrome phenotypes. Gynecological Endocrinology, 2018, 34, 518-523.	0.7	28
36	Follicular fluid steroid and epidermal growth factor content, and in vitro estrogen release by granulosa-luteal cells from patients with polycystic ovaries in an IVF/ET program. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1991, 42, 195-199.	0.5	27

#	Article	IF	CITATIONS
37	Comparison of different anaesthetic methodologies for sedation during (i) in vitro (li) fertilization procedures: effects on patient physiology and oocyte competence. Gynecological Endocrinology, 2012, 28, 796-799.	0.7	26
38	Regulatory Functions of L-Carnitine, Acetyl, and Propionyl L-Carnitine in a PCOS Mouse Model: Focus on Antioxidant/Antiglycative Molecular Pathways in the Ovarian Microenvironment. Antioxidants, 2020, 9, 867.	2.2	26
39	Therapeutic strategies for ovulation induction in infertile women with polycystic ovary syndrome. Gynecological Endocrinology, 2005, 21, 340-352.	0.7	25
40	Growth factors and folliculogenesis in polycystic ovary patients. Expert Review of Endocrinology and Metabolism, 2007, 2, 215-223.	1,2	22
41	Brain derived neurotrophic factor circulating levels in patients undergoing IVF. Journal of Assisted Reproduction and Genetics, 2007, 24, 477-480.	1.2	22
42	Pre-conceptional maternal exposure to cyclophosphamide results in modifications of DNA methylation in F1 and F2 mouse oocytes: evidence for transgenerational effects. Epigenetics, 2019, 14, 1057-1064.	1.3	22
43	Oxidative Stress Measurement in Frozen/Thawed Human Sperm: The Protective Role of an In Vitro Treatment with Myo-Inositol. Antioxidants, 2022, 11, 10.	2.2	21
44	Ultrasonographic and color Doppler analysis in the treatment of polycystic ovary syndrome. Ultrasound in Obstetrics and Gynecology, 1998, 12, 180-187.	0.9	20
45	Inositol and In Vitro Fertilization with Embryo Transfer. International Journal of Endocrinology, 2017, 2017, 1-5.	0.6	20
46	Respiratory Mitochondrial Efficiency and DNA Oxidation in Human Sperm after In Vitro Myo-Inositol Treatment. Journal of Clinical Medicine, 2020, 9, 1638.	1.0	20
47	Brain-Derived Neurotrophic Factor in Plasma of Women with Endometriosis. Journal of Endometriosis, 2010, 2, 144-150.	1.0	18
48	Polycystic ovary syndrome: brain-derived neurotrophic factor (BDNF) plasma and follicular fluid levels. Gynecological Endocrinology, 2012, 28, 241-244.	0.7	18
49	Increased levels of oxidative and carbonyl stress markers in normal ovarian cortex surrounding endometriotic cysts. Gynecological Endocrinology, 2014, 30, 808-812.	0.7	18
50	PCOS and pregnancy: a review of available therapies to improve the outcome of pregnancy in women with polycystic ovary syndrome. Expert Review of Endocrinology and Metabolism, 2018, 13, 87-98.	1.2	16
51	Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors. Biomedicine and Pharmacotherapy, 2008, 62, 373-377.	2.5	14
52	Conventional IVF as a laboratory strategy to rescue fertility potential in severe poor responder patients: the impact of reproductive aging. Gynecological Endocrinology, 2013, 29, 997-1001.	0.7	14
53	Metabolic and Molecular Mechanisms of Diet and Physical Exercise in the Management of Polycystic Ovarian Syndrome. Biomedicines, 2022, 10, 1305.	1.4	14
54	Doppler analysis of uterine blood flow changes in spontaneous and medically induced menopause. Gynecological Endocrinology, 1995, 9, 143-148.	0.7	13

#	Article	IF	Citations
55	Impact of Italian legislation regulating assisted reproduction techniques on ICSI outcomes in severe male factor infertility: a multicentric survey. Human Reproduction, 2007, 22, 2481-2487.	0.4	13
56	Modulating Intrafollicular Hormonal Milieu in Controlled Ovarian Stimulation: Insights From PPAR Expression in Human Granulosa Cells. Journal of Cellular Physiology, 2016, 231, 908-914.	2.0	13
57	Effect of <scp>d</scp> -chiro-inositol and alpha-lipoic acid combination on COH outcomes in overweight/obese PCOS women. Gynecological Endocrinology, 2020, 36, 755-759.	0.7	13
58	Hemodynamic, hematological and hemorrheological evaluation of post-term pregnancy. Acta Obstetricia Et Gynecologica Scandinavica, 1995, 74, 336-340.	1.3	12
59	Color Doppler hysterosalpingography in the diagnosis of tubal patency. Fertility and Sterility, 1996, 65, 317-322.	0.5	12
60	Vascular endothelial growth factor in females of reproductive age. Gynecological Endocrinology, 2003, 17, 477-492.	0.7	12
61	Inside the granulosa transcriptome. Gynecological Endocrinology, 2016, 32, 951-956.	0.7	12
62	Endometrial Dysbiosis Is Related to Inflammatory Factors in Women with Repeated Implantation Failure: A Pilot Study. Journal of Clinical Medicine, 2022, 11, 2481.	1.0	12
63	Evidence that granulosa cells inhibit interleukin-1? and interleukin-2 production from follicular lymphomonocytes. Journal of Assisted Reproduction and Genetics, 1993, 10, 517-522.	1.2	11
64	Vascular endothelial growth factor and its soluble receptor in ovarian pathology. Gynecological Endocrinology, 2005, 21, 50-56.	0.7	11
65	Estrogen treatment in infertile women with premature ovarian insufficiency in transitional phase: a retrospective analysis. Journal of Assisted Reproduction and Genetics, 2018, 35, 475-482.	1.2	11
66	Exploring Epithelial–Mesenchymal Transition Signals in Endometriosis Diagnosis and In Vitro Fertilization Outcomes. Biomedicines, 2021, 9, 1681.	1.4	11
67	Progestins Modulate the Action of Estrogen on Gonadotropin-Releasing Hormone, Luteinizing Hormone and Prolactin in the Rat. Gynecologic and Obstetric Investigation, 1990, 29, 197-202.	0.7	10
68	Transdermal hormone replacement therapy and Doppler findings in normal and overweight postmenopausal patients. Gynecological Endocrinology, 2004, 19, 274-281.	0.7	10
69	A randomized control comparison study of culture media (HTF versus P1) for human in vitro fertilization. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2004, 116, 196-200.	0.5	10
70	Transdermal HRT and Doppler findings in normotensive and hypertensive postmenopausal patients. Ultrasound in Obstetrics and Gynecology, 2005, 26, 546-551.	0.9	10
71	Different stimulation protocols for oocyte cryropreservation in oncological patients: a retrospective analysis of single university centre. Gynecological Endocrinology, 2015, 31, 966-970.	0.7	10
72	A comparative study of three ovulation induction protocols in polycystic ovarian disease patients in an in vitro fertilization/embryo transfer program. Journal of Assisted Reproduction and Genetics, 1993, 10, 15-20.	1.2	9

#	Article	IF	Citations
73	Vascular endothelial growth factor level changes during human embryo development in culture medium. Gynecological Endocrinology, 2008, 24, 184-187.	0.7	9
74	<scp> </scp> -arginine plus drospirenone-ethinyl estradiol in the treatment of patients with PCOS: a prospective, placebo controlled, randomised, pilot study. Gynecological Endocrinology, 2010, 26, 861-868.	0.7	9
75	Carnitines as Mitochondrial Modulators of Oocyte and Embryo Bioenergetics. Antioxidants, 2022, 11, 745.	2.2	9
76	Genetic screening in Italian infertile couples undergoing intrauterine insemination andin vitrofertilization techniques: a multicentric study. Gynecological Endocrinology, 2011, 27, 453-457.	0.7	8
77	Assisted reproductive technique in women of advanced fertility age. Minerva Ginecologica, 2018, 70, 738-749.	0.8	8
78	Chromosomal abnormalities in women with premature ovarian failure. Gynecological Endocrinology, 2010, 26, 717-724.	0.7	7
79	Pharmacotherapy of ovarian hyperstimulation syndrome. Expert Opinion on Pharmacotherapy, 2010, 11, 2527-2534.	0.9	5
80	Pregnancy following regression of uterine submucosal leiomyoma with GnRH therapy; a case report. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1991, 39, 223-225.	0.5	4
81	Comparison between GnRH agonist and antagonist protocols for severe endometriosis in assisted reproductive cycles. Journal of Endometriosis, 2012, 4, 42-47.	1.0	3
82	Over Hypothyroidism in a Woman Undergoing Controlled Ovarian Hyperstimulation. Endocrine Practice, 2014, 20, e11-e13.	1.1	3
83	Difficult-to-treat women for controlled ovarian hyperstimulation: tips and tricks. Expert Review of Endocrinology and Metabolism, 2011, 6, 617-627.	1.2	2
84	Clinical utility of adjuvant growth hormone in the treatment of patients with polycystic ovaries undergoing in vitro fertilization. Journal of Assisted Reproduction and Genetics, 1997, 14, 4-7.	1.2	1
85	Metformin metabolic and vascular effects in overweight/moderately obese hyperinsulinemic PCOS patients treated with contraceptive vaginal ring: a pilot study. Gynecological Endocrinology, 2019, 35, 854-861.	0.7	1
86	Metformin metabolic and vascular effects in normal weight hyperinsulinemic polycystic ovary syndrome patients treated with contraceptive vaginal ring. A pilot study. Gynecological Endocrinology, 2020, 36, 1062-1069.	0.7	1
87	Daily Variation of Plasma Brain-derived Neurotrophic Factor in Women with Endometriosis. Journal of Endometriosis, 2011, 3, 40-46.	1.0	1
88	Doppler Analysis in Pregnancies Complicated by Pregnancy-Induced Hypertension and Fetal Growth Retardation. Hypertension in Pregnancy, 1993, 12, 121-127.	0.5	0
89	Biomarkers of Ovarian Ageing. ISGE Series, 2016, , 47-51.	0.2	0
90	Female Infertility and Autoimmunity. ISGE Series, 2018, , 85-92.	0.2	0

#	Article	IF	CITATIONS
91	†Primary gingival and later primary vulval carcinomas arising in lichen planus: report of a case and clinical suggestions for diagnosis of a neglected disease'. Gynecological Endocrinology, 2019, 35, 938-940.	0.7	0
92	In Patients with Only One or Two Oocytes, Is IVF-ET or ICSI Better?. ISGE Series, 2015, , 111-117.	0.2	0
93	Supplementation with DHEA in Poor Responder Patients. ISGE Series, 2015, , 119-127.	0.2	0
94	Gene Expression in Cumulus Cells and Oocyte Quality. ISGE Series, 2016, , 39-44.	0.2	0